Can folic acid protect against congenital heart defects in down syndrome?
โ Scribed by Willemijn M. Meijer; Martha M. Werler; Carol Louik; Sonia Hernandez-Diaz; Lolkje T.W. de Jong-van den Berg; Allen A. Mitchell
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 74 KB
- Volume
- 76
- Category
- Article
- ISSN
- 1542-0752
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
Several studies have suggested a protective effect of folic acid (fa) on congenital heart anomalies. down syndrome (ds) infants are known to have a high frequency of heart anomalies. not all children with ds suffer from heart anomalies, which raises the question whether maternal factors might affect the risk of these anomalies. our objectives were to investigate whether first-trimester fa use protects against heart anomalies among ds children.
Methods:
Women with liveborn ds children participating in the slone epidemiology center birth defects study between 1976 and 1997 were included. we performed case-control analyses using ds, with heart anomalies as cases and ds, without heart anomalies as controls. subanalyses were performed for defects that have been associated with fa in non-ds populations (conotruncal, ventricular septal [vsd]) and for those that are associated with ds (ostium secundum type atrial septal defects [asd] and endocardial cushion defects [ecd]). exposure was defined as the use of any fa-containing product for an average of at least 4 days per week during the first 12 weeks of pregnancy, whereas no exposure was defined as no use of fa in these 12 weeks.
Results:
Of the 223 cases, 110 (49%) were exposed versus 84 (46%) of the 184 controls. after adjustment for possible confounders, no protective effect of fa was found on heart anomalies overall (or 0.95, 95% ci: 0.61-1.47) nor separately for conotruncal defects, vsds, asds, or ecds.
Conclusions:
Our study does not show a protective effect of fa on heart anomalies among infants with ds.
๐ SIMILAR VOLUMES
The purpose of this study was to determine whether there are important differences in maternal and environmental prenatal risk factors between liveborn Down syndrome infants with congenital heart defects and Down syndrome infants without heart defects. Using a case control study design, we evaluated
## Background: Maternal folic acid supplementation has been associated with a reduced risk for neural tube defects and may be associated with a reduced risk for congenital heart defects and other birth defects. individuals with down syndrome are at high risk for congenital heart defects and have be
## Abstract Cardiac abnormalities are one of the most common congenital defects observed in individuals with Down syndrome. Considerable research has implicated both folate deficiency and genetic variation in folate pathway genes with birth defects, including both congenital heart defects (CHD) and